Nuclear Medicine

Nuclear Medicine
Audio Summaries

The literature in nuclear medicine doesn't slow down, and the papers you skip might be the ones that change your practice. OSLR turns the journals you'd read if you had the time into 3-minute audio summaries. Listen on your commute, between cases, whenever.

4 active journals696 audio summaries

Recent summaries

The latest articles summarized from nuclear medicine journals.

Myocardial Extraction Fraction and Circulation-Dependent Changes of 99mTc-4BOH: Implications for Quantitative SPECT Myocardial Perfusion Imaging.

Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology|Nov 20, 2026

99mTc-4BOH, a novel SPECT tracer, was evaluated for quantitative myocardial perfusion imaging by measuring its myocardial extraction fraction (EF) in isolated rat hearts across a range of flow rates and comparing it with 99mTc-Teboroxime and 99mTc-Sestamibi. The tracer showed consistently high, flow-independent EF (96.5%-99.5%) and greater myocardial retention than Teboroxime, but its EF declined over time after circulation (to about 84% at 2 min and 57% at 10 min), with erythrocyte interaction identified as a contributing factor. The authors conclude that early post-injection imaging may be preferable for myocardial blood flow quantification with this tracer.

Spontaneous coronary artery dissection: implications for women's health, clinical care, and future research.

Lancet (London, England)|Nov 19, 2026

Spontaneous coronary artery dissection (SCAD) is an increasingly recognized cause of acute coronary syndromes, mainly affecting younger women, and is likely more common than previously thought. This Review synthesizes current evidence on SCAD's epidemiology, mechanisms (including genetic susceptibility), diagnosis, management, and implications for reproductive and women's health. It also identifies research priorities, since evidence guiding pharmacological and interventional treatment remains scarce, even though most patients heal spontaneously and are best managed conservatively.

Seasonal mass vaccination with R21/Matrix-M against malaria in The Gambia and Burkina Faso: an open-label, cluster-randomised, controlled trial.

Lancet (London, England)|Nov 19, 2026

This cluster-randomised trial asked whether seasonal mass vaccination with the R21/Matrix-M malaria vaccine, given before peak transmission, could reduce malaria infection prevalence and be safe in The Gambia (low-to-moderate transmission) and Burkina Faso (intense seasonal transmission). Across 54 villages, three monthly doses reduced the odds of P. falciparum infection at peak transmission by 70% in The Gambia (aOR 0.30) and by 25% in Burkina Faso (aOR 0.75), with the vaccine judged safe and well tolerated. The authors conclude that seasonal mass vaccination could be an additional malaria control strategy in seasonal transmission settings, though its effect was considerably larger in The Gambia than in Burkina Faso.

Reproductive health in women in Britain from 2010 to 2024: findings from repeated, cross-sectional National Surveys of Sexual Attitudes and Lifestyles (Natsal).

Lancet (London, England)|Nov 19, 2026

This study compares reproductive health indicators among women aged 16-54 in Britain using nationally representative Natsal surveys from 2010-2012 (Natsal-3) and 2022-2024 (Natsal-4), asking whether reproductive autonomy has improved and how it varies across social groups. Key findings include an increase in lifetime abortion (16.0% to 20.7%), a rise in women aged 16-44 reporting they definitely do not want children (7.7% to 16.6%), and a sharp drop in hormonal contraception use among women under 35. Persistent gaps remain: 18.5% of women at risk of unintended pregnancy reported no effective contraception, and women with lower education, greater deprivation, or Black African/Caribbean/Black British ethnicity faced higher risks of no effective contraception and abortion.

Assessing Multiple Treatment Regimens for Tuberculosis.

The New England journal of medicine|Nov 19, 2026

This phase 2 randomized trial (PARADIGM4TB) asked whether new four-drug regimens containing ganfeborole and/or BTZ-043 could shorten or improve tuberculosis treatment compared with the standard 24-week HRZE regimen, using early sputum culture clearance (log10 time-to-positivity slope) as the primary measure. Two regimens, ganfeborole-bedaquiline-pretomanid-moxifloxacin (BPMG) and BTZ-043-bedaquiline-delamanid-moxifloxacin (BDMT), showed a posterior probability of superiority over HRZE of 0.83 and 0.99, respectively, with acceptable safety profiles to advance to further evaluation. The results were used to select regimens for further study rather than to establish definitive efficacy.

Acute Respiratory Distress Syndrome.

The New England journal of medicine|Nov 18, 2026

This review by Calfee and McAuley summarizes the current understanding of acute respiratory distress syndrome (ARDS), a common cause of acute hypoxemic respiratory failure. It addresses the key management challenges, including treating the underlying trigger, avoiding ventilator-induced lung injury and volume overload, and resolving controversies around supporting nonintubated patients, personalizing positive end-expiratory pressure, using innovative ventilation strategies, and giving glucocorticoids. The authors also highlight whether precision medicine approaches based on biologic, radiographic, or physiologic subphenotypes can improve outcomes.

Natural ligand-based CAR T-cell therapy targeting BCMA and TACI for relapsed or refractory multiple myeloma (TriPRIL): a non-randomised, phase 1, first-in-human trial.

Lancet (London, England)|Nov 17, 2026

This first-in-human phase 1 trial tested TriPRIL, an autologous CAR T-cell therapy that uses an engineered trimeric form of the natural ligand APRIL to simultaneously target BCMA and TACI, aiming to reduce antigen escape in relapsed or refractory multiple myeloma. In 15 infused patients (nine of whom had prior BCMA-directed CAR T therapy), the therapy showed a manageable safety profile, with no dose-limiting toxicities or treatment-related deaths, and cytokine release syndrome was limited to grade 1-2. The recommended phase 2 dose was set at 3.0 × 10^8 cells, supporting further investigation of this dual-targeted, natural ligand-based approach.

Semaglutide for the Treatment of Obesity in Children 6 to <12 Years of Age.

The New England journal of medicine|Nov 16, 2026

This phase 3, double-blind, placebo-controlled trial asked whether once-weekly semaglutide could safely and effectively reduce body-mass index in children aged 6 to under 12 years with obesity, a group with few durable medical treatment options. Among 167 children randomized 2:1 to semaglutide or placebo alongside lifestyle counseling, semaglutide produced a mean BMI reduction of 13.5% versus a 2.7% increase with placebo at week 68 (between-group difference -16.2 percentage points). Gastrointestinal adverse events were more common with semaglutide, but led to discontinuation in only one participant in that group.

Relationship between integrated myocardial flow reserve and obstructive coronary artery disease and major adverse cardiac events: Findings from the multicenter REFINE PET Registry.

Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology|Nov 13, 2026

This multicenter REFINE PET study asked whether integrated myocardial flow reserve (iMFR), which combines MFR with focal perfusion defects to separate epicardial from microvascular disease, improves detection of obstructive coronary artery disease (CAD) and prediction of major adverse cardiac events (MACE). In 2,869 patients without prior CAD who had angiography, the extent of focally impaired myocardium outperformed conventional minimal-segment MFR for diagnosing obstructive CAD (AUC 0.77 vs 0.73) but performed similarly to ischemic TPD and physician visual scoring. For MACE prediction across 34,761 registry patients, the extent of diffusely impaired myocardium carried the most prognostic information (C-statistic 0.723), slightly exceeding global MFR and focally impaired myocardium.

Lynch syndrome.

Lancet (London, England)|Nov 12, 2026

Lynch syndrome, caused by germline mismatch repair gene variants, is the most common inherited cancer predisposition syndrome, yet most carriers remain undiagnosed. This review asks how scientific advances in biology, diagnosis, prevention, and treatment can be translated into equitable, effective care across the full continuum, from case identification through cascade testing. The authors highlight that universal tumour testing and immune checkpoint inhibitors have transformed the field, but that inconsistent implementation and access gaps continue to limit benefit.

Start listening to nuclear medicine research

14-day free trial. Pick your journals and go.